Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
NY-338
i
Other names:
NY-338, CYT-338, CD38 NKp46 FLEX NK engager
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
NAYA Therapeutics
Drug class:
CD38 inhibitor, CD16 agonist, Natural cytotoxicity triggering receptor 1 agonist
Related drugs:
‹
daratumumab (26)
isatuximab-irfc (11)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
BHV-1100 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
GEN3014 (0)
SAR650984 SC (0)
TAK-573 (0)
FT516 (1)
GTB-5550 (1)
IPH6101 (1)
NY-303 (0)
daratumumab (26)
isatuximab-irfc (11)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
BHV-1100 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
GEN3014 (0)
SAR650984 SC (0)
TAK-573 (0)
FT516 (1)
GTB-5550 (1)
IPH6101 (1)
NY-303 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.